[{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama Sa","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Horama Sa","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Horama Sa"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Waterloo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Waterloo \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Waterloo \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Kedrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kedrion \/ Undisclosed"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irvine School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Florida Lions Eye Bank","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Plasma Rich In Growth Factors","moa":"Growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Florida Lions Eye Bank","highestDevelopmentStatusID":"1","companyTruncated":"University of Miami \/ Florida Lions Eye Bank"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Nutrarex Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Nutrarex Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Nutrarex Biotech"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Mantis Photonics","sponsor":"Sundets \u00d6gonl\u00e4kare","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tropicamide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mantis Photonics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mantis Photonics \/ Sundets \u00d6gonl\u00e4kare","highestDevelopmentStatusID":"1","companyTruncated":"Mantis Photonics \/ Sundets \u00d6gonl\u00e4kare"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ China Medical University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Kubota Pharmaceutical \/ China Medical University Hospital"},{"orgOrder":0,"company":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","sponsor":"OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"PARP1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa"},{"orgOrder":0,"company":"Calm Water Therapeutics","sponsor":"Andover Research Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; Adenine DNA glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Calm Water Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calm Water Therapeutics \/ Andover Research Eye Institute","highestDevelopmentStatusID":"1","companyTruncated":"Calm Water Therapeutics \/ Andover Research Eye Institute"},{"orgOrder":0,"company":"Josip Juraj Strossmayer University of Osijek","sponsor":"Plava Medical Group, Bosna and Herzegovina","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Josip Juraj Strossmayer University of Osijek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Josip Juraj Strossmayer University of Osijek \/ Plava Medical Group, Bosna and Herzegovina","highestDevelopmentStatusID":"1","companyTruncated":"Josip Juraj Strossmayer University of Osijek \/ Plava Medical Group, Bosna and Herzegovina"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"He Eye Hospital","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Diquafosol","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"He Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"He Eye Hospital \/ Santen Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"He Eye Hospital \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"The Norwegian Dry Eye Clinic","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NORWAY","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"The Norwegian Dry Eye Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Norwegian Dry Eye Clinic \/ Laboratoires Thea","highestDevelopmentStatusID":"1","companyTruncated":"The Norwegian Dry Eye Clinic \/ Laboratoires Thea"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Shanghai BDgene","sponsor":"Beijing Tongren Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BD113 vVLP","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shanghai BDgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai BDgene \/ Beijing Tongren Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene \/ Beijing Tongren Hospital"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0.95999999999999996,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.95999999999999996,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecular Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Glory Kingdom Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Bilberry","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Glory Kingdom Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Glory Kingdom Corporation"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Black Tomato Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhongshan Ophthalmic Center, Sun Yat-sen University","sponsor":"Blackmores (China) CO., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Carotenoids","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Zhongshan Ophthalmic Center, Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongshan Ophthalmic Center, Sun Yat-sen University \/ Blackmores (China) CO., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Zhongshan Ophthalmic Center, Sun Yat-sen University \/ Blackmores (China) CO., Ltd"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACRO Biomedical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Bruder Healthcare","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Dry Eye Drink","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bruder Healthcare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bruder Healthcare \/ CBCC Global","highestDevelopmentStatusID":"1","companyTruncated":"Bruder Healthcare \/ CBCC Global"},{"orgOrder":0,"company":"Bio Nature Health","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Eye Empower","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bio Nature Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bio Nature Health \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bio Nature Health \/ Citruslabs"},{"orgOrder":0,"company":"Wills Eye Hospital","sponsor":"Guardian Health Sciences, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Glaucocetin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Wills Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wills Eye Hospital \/ Guardian Health Sciences, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Wills Eye Hospital \/ Guardian Health Sciences, Inc."},{"orgOrder":0,"company":"Institut de la Macula y la Retina","sponsor":"Igen BioLab SLU","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"IGENH35.3A","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Institut de la Macula y la Retina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut de la Macula y la Retina \/ Igen BioLab SLU","highestDevelopmentStatusID":"1","companyTruncated":"Institut de la Macula y la Retina \/ Igen BioLab SLU"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Innostellar Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LX102-C01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai General Hospital \/ Innostellar Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai General Hospital \/ Innostellar Biotherapeutics"},{"orgOrder":0,"company":"Shih Chien Huang","sponsor":"Febico (Far East Bio-Tec Co Ltd)","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Multicomponent Dietary Supplement","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shih Chien Huang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shih Chien Huang \/ Febico (Far East Bio-Tec Co Ltd)","highestDevelopmentStatusID":"1","companyTruncated":"Shih Chien Huang \/ Febico (Far East Bio-Tec Co Ltd)"},{"orgOrder":0,"company":"Nu Eyne Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Nu Eyne M02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Nu Eyne Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nu Eyne Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nu Eyne Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutritears","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Nutrof","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ Laboratoires Thea","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ Laboratoires Thea"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LGC Group GB \/ OliX Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceutical"},{"orgOrder":0,"company":"Western University of Health Sciences","sponsor":"Guardion Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Omegaboost","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Western University of Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Western University of Health Sciences \/ Guardion Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Western University of Health Sciences \/ Guardion Health Sciences"},{"orgOrder":0,"company":"Institut de la Macula y la Retina","sponsor":"Igen BioLab SLU","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Postbotic","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Institut de la Macula y la Retina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut de la Macula y la Retina \/ Igen BioLab SLU","highestDevelopmentStatusID":"1","companyTruncated":"Institut de la Macula y la Retina \/ Igen BioLab SLU"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Retilut","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laboratoires Thea \/ Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Thea \/ Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica"},{"orgOrder":0,"company":"University of Alicante","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Alicante","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alicante \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"University of Alicante \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"University of Alicante","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Alicante","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alicante \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"University of Alicante \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"Essilor-Polylite Taiwan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Stellest Lenses","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Essilor-Polylite Taiwan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essilor-Polylite Taiwan \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Essilor-Polylite Taiwan \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"T7082","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Sight Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tearcare System","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Sight Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Sight Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sight Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Ecolite Group","sponsor":"UCSI University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Twinkle Eyez","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ecolite Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecolite Group \/ UCSI University","highestDevelopmentStatusID":"1","companyTruncated":"Ecolite Group \/ UCSI University"},{"orgOrder":0,"company":"Abilion Medical Systems AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Walther System","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Abilion Medical Systems AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abilion Medical Systems AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abilion Medical Systems AB \/ Undisclosed"},{"orgOrder":0,"company":"Rothschild Foundation Hospital","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Rothschild Foundation Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rothschild Foundation Hospital \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Rothschild Foundation Hospital \/ Bayer AG"},{"orgOrder":0,"company":"Berner Augenklinik","sponsor":"Medignition","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Berner Augenklinik","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berner Augenklinik \/ medignition","highestDevelopmentStatusID":"1","companyTruncated":"Berner Augenklinik \/ medignition"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKi2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikarovec \/ UKi2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKi2S"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":1.8999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Partners Group"},{"orgOrder":0,"company":"Istanbul Medipol University Hospital","sponsor":"Varol TUNALI | Liv Hospital (Ulus)","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TURKEY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Istanbul Medipol University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Istanbul Medipol University Hospital \/ Varol TUNALI | Liv Hospital (Ulus)","highestDevelopmentStatusID":"1","companyTruncated":"Istanbul Medipol University Hospital \/ Varol TUNALI | Liv Hospital (Ulus)"},{"orgOrder":0,"company":"Lumenis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Lumenis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumenis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lumenis \/ Undisclosed"},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"GelMEDIX \/ HTL Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL Biotechnology"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Melatonin receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Palatin Technologies","amount2":0.33000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Palatin Technologies \/ Boehringer Ingelheim GmbH"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Bimatoprost is a HPAPI drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma, Open-Angle.

                          Product Name : Undisclosed

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          April 21, 2022

                          Lead Product(s) : Bimatoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Study Phase : Undisclosed

                          Sponsor : Partners Group

                          Deal Size : $1,900.0 million

                          Deal Type : Acquisition

                          Details : Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 19, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Partners Group

                          Deal Size : $1,900.0 million

                          Deal Type : Acquisition

                          Pharmathen

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Bimatoprost is a HPAPI drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Cataract.

                          Product Name : Undisclosed

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          September 04, 2025

                          Lead Product(s) : Bimatoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Istanbul Medipol University Hospital

                          Country arrow
                          FNCE
                          Not Confirmed

                          Istanbul Medipol University Hospital

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 29, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Varol TUNALI | Liv Hospital (Ulus)

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The collaboration strengthens Boehringer’s innovative and diversified pipeline in retinal conditions and its underlying commitment to vision preservation and protection.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 18, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $327.6 million

                          Deal Type : Collaboration

                          blank

                          06

                          Bio Nature Health

                          Country arrow
                          FNCE
                          Not Confirmed

                          Bio Nature Health

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Eye Empower is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 14, 2025

                          Lead Product(s) : Eye Empower

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Citruslabs

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Università degli Studi 'G. d'Annunzio' Chieti e Pescara

                          Country arrow
                          FNCE
                          Not Confirmed

                          Università degli Studi 'G. d'Annunzio' Chieti e Pescara

                          Country arrow
                          FNCE
                          Not Confirmed

                          Lead Product(s) : Nicotinamide

                          Therapeutic Area : Ophthalmology

                          Study Phase : Undisclosed

                          Sponsor : OFFHEALTH S.p.A. | Università degli Studi di Sassari | University of Pisa

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 05, 2025

                          Lead Product(s) : Nicotinamide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : OFFHEALTH S.p.A. | Università degli Studi di Sassari | University of Pisa

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Shih Chien Huang

                          Country arrow
                          FNCE
                          Not Confirmed

                          Shih Chien Huang

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Multicomponent Dietary Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Multicomponent Dietary Supplement

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Febico (Far East Bio-Tec Co Ltd)

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Novelty Nobility

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Ecolite Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Ecolite Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Twinkle Eyez is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 28, 2024

                          Lead Product(s) : Twinkle Eyez

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : UCSI University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank